全文获取类型
收费全文 | 106446篇 |
免费 | 8521篇 |
国内免费 | 6155篇 |
专业分类
耳鼻咽喉 | 549篇 |
儿科学 | 2495篇 |
妇产科学 | 1229篇 |
基础医学 | 18126篇 |
口腔科学 | 1737篇 |
临床医学 | 8920篇 |
内科学 | 22185篇 |
皮肤病学 | 1504篇 |
神经病学 | 6939篇 |
特种医学 | 2139篇 |
外国民族医学 | 31篇 |
外科学 | 6804篇 |
综合类 | 17755篇 |
现状与发展 | 27篇 |
一般理论 | 1篇 |
预防医学 | 6027篇 |
眼科学 | 1964篇 |
药学 | 10243篇 |
10篇 | |
中国医学 | 2868篇 |
肿瘤学 | 9569篇 |
出版年
2024年 | 185篇 |
2023年 | 1064篇 |
2022年 | 2205篇 |
2021年 | 2959篇 |
2020年 | 2748篇 |
2019年 | 3350篇 |
2018年 | 3240篇 |
2017年 | 3224篇 |
2016年 | 3473篇 |
2015年 | 3691篇 |
2014年 | 5724篇 |
2013年 | 7202篇 |
2012年 | 5734篇 |
2011年 | 6785篇 |
2010年 | 5401篇 |
2009年 | 5366篇 |
2008年 | 5620篇 |
2007年 | 6117篇 |
2006年 | 5702篇 |
2005年 | 5221篇 |
2004年 | 4670篇 |
2003年 | 4147篇 |
2002年 | 3579篇 |
2001年 | 3268篇 |
2000年 | 2762篇 |
1999年 | 2371篇 |
1998年 | 2041篇 |
1997年 | 1863篇 |
1996年 | 1370篇 |
1995年 | 1263篇 |
1994年 | 1012篇 |
1993年 | 722篇 |
1992年 | 586篇 |
1991年 | 461篇 |
1990年 | 378篇 |
1989年 | 291篇 |
1988年 | 233篇 |
1987年 | 192篇 |
1985年 | 550篇 |
1984年 | 623篇 |
1983年 | 486篇 |
1982年 | 461篇 |
1981年 | 438篇 |
1980年 | 386篇 |
1979年 | 343篇 |
1978年 | 287篇 |
1977年 | 214篇 |
1976年 | 255篇 |
1975年 | 261篇 |
1974年 | 200篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的探讨脊髓小脑共济失调2型(SCA2)致病基因ATXN2异常等位基因中间重复个体的表型和分子遗传学特点。方法针对2005—2018年中日友好医院神经科运动障碍与神经遗传病研究中心收集的1383个常染色体显性遗传共济失调家系的先证者和部分家系成员,采用荧光标记毛细管电泳片段分析方法进行动态突变检测,对携带ATXN2基因中间重复的个体进行临床表型和遗传特征分析。结果共检出163个家系(包含先证者和家系成员共203人)携带异常扩展的ATXN2基因CAG重复序列,其中93个家系中有107例的异常扩展等位基因重复次数在29~34次之间。在其中的20个亲子对中,父系遗传16个,异常等位基因的代间扩展增加0~28次,母系遗传4个,异常等位基因的代间扩展增加0~4次。结论对于临床拟诊SCA2家系患者,需对其亲代或成年子代个体进行ATXN2基因检测,以免漏诊。动态突变基因检测有助于识别中间重复的个体,对明确家系致病基因和遗传咨询至关重要。 相似文献
3.
4.
目的:观察理筋通督手法治疗颈性眩晕的临床疗效。方法:将120例颈性眩晕患者随机分成3组,理筋通督组、传统手法组及安慰剂组。理筋通督组采用理筋通督手法;传统手法组采用传统手法;安慰剂组口服维生素C。结果:理筋通督手法可显著减缓患者基底动脉舒张期最低血流速度(P0.05)。理筋通督组有效率为93.67%,传统手法组有效率为67.5%,安慰剂组有效率为17.5%,3组比较差异有统计学意义(P0.05),理筋通督组明显优于其他两组。结论:理筋通督手法治疗颈性眩晕临床疗效显著。 相似文献
5.
《Clinical neurophysiology》2020,131(7):1444-1452
ObjectiveTo investigate cognitive functions in non-demented patients with early-onset Parkinson's disease (PD), and to compare PARK2 gene mutation carriers and non-carriers by means of event-related brain potentials (ERPs).MethodsThe participants comprised patients with early-onset PD (EOPD) and healthy controls (HC). Patients with EOPD were divided into two groups as carriers of known pathogenic variants of PARK2 gene (EOPD-PC) and non-carriers of genes involved in familial PD (EOPD-NC). ERP data were collected during auditory oddball and visual continuous performance test (CPT).ResultsBoth EOPD groups (EOPD-PC and EOPD-NC) displayed reduced and delayed P3 in response to oddball target and CPT NoGo. CPT Go P3 was reduced in EOPD-NC but not in EOPD-PC. Oddball target N1 was reduced and P2 was enhanced in both EOPD-PC and EOPD-NC. In both cognitive tasks, RTs were prolonged and accuracy was lower in EOPD-PC and EOPD-NC.ConclusionsWe found several EOPD-related neurophysiologic changes, implying impairments in cognitive functions. Pairwise comparisons between EOPD-PC and EOPD-NC revealed no significant ERP marker.SignificanceIn this study, the confounding effect of normative aging was somewhat excluded compared with many previous studies. In contrast with the many oddball studies in non-demented PD, we clearly observed reduced and prolonged P3 in early-onset PD. Our NoGo P3 findings also contribute to the limited ERP research concerning response inhibition. 相似文献
6.
7.
8.
《Revista espa?ola de anestesiología y reanimación》2020,67(5):245-252
Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds.In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). Vitamin C, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitamin C in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves.Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal. 相似文献
9.
Yesim Aydinok 《ISBT科学丛刊》2020,15(1):102-109
Lifetime red cell concentrate (RCC) transfusions still account for significant iron overload‐related morbidity and mortality despite chelation therapy in thalassaemia. The cumulative risk of transfusion‐transmitted infections is substantial for thalassaemia patients. Pathogen reduction technologies for RCC may imply a proactive approach against new/re‐emerging pathogens and may be an ultimate safeguard for transfusion safety in the developing countries. Red cell alloimmunization may become a significant clinical challenge in thalassaemia. The availability of high‐throughput molecular blood group antigen typing in the donors may allow perfect match transfusion, beyond ABO‐D and CEK antigen‐matched transfusions. Allogeneic stem cell transplantation (A‐SCT) is the only available curative therapy in thalassaemia, but carries a substantial risk of serious adverse events and mortality. Gene addition therapy for correction of the α‐globin chain imbalance overcomes the problems of donor availability and immunological complications of A‐SCT. Gene editing by either gene disruption or correction emerged as a potential alternative to gene addition therapy in beta‐thalassaemia. A new era of novel therapeutics targeting α/β imbalance, ineffective erythropoiesis or iron dysregulation is unfolding in thalassaemia management, and a number of those now have agents in preclinical and clinical development. Hydroxyurea (HU) may improve globin chain imbalance and be beneficial for reducing or omitting transfusion requirement. Ruxolitinib has allowed steady decrease in spleen volume that may serve for avoiding splenectomy in beta‐thalassaemia. Luspatercept may restore normal erythroid differentiation and improve anaemia. Hepcidin mimetics or TMPRSS6 inhibitors may modulate ineffective erythropoiesis by iron restriction and improve anaemia and organ iron loading. 相似文献
10.